Article Text

other Versions

PDF
-463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis
  1. C Salvarani (salvarani.carlo{at}asmn.re.it)
  1. Arcispedale S Maria Nuova, Italy
    1. B Casali (casali.bruno{at}asmn.re.it)
    1. Arcispedale S Maria Nuova, Italy
      1. E Farnetti (farnetti.enrico{at}asmn.re.it)
      1. Arcispedale S Maria Nuova, Italy
        1. N Pipitone (pipitone.nicolo{at}asmn.re.it)
        1. Arcispedale S Maria Nuova, Italy
          1. D Nicoli (nicoli.davide{at}asmn.re.it)
          1. Arcispedale S Maria Nuova, Italy
            1. P Macchioni (macchioni.pierluigi{at}asmn.re.it)
            1. Arcispedale S Maria Nuova, Italy
              1. L Cimino (cimino.luca{at}asmn.re.it)
              1. Arcispedale S Maria Nuova, Italy
                1. G Bajocchi (baiocchi.gianluigi{at}asmn.re.it)
                1. Arcispedale S Maria Nuova, Italy
                  1. M Catanoso (catanoso.mariagrazia{at}asmn.re.it)
                  1. Arcispedale S Maria Nuova, Italy
                    1. L Pattacini (pattacini.laura{at}asmn.re.it)
                    1. Arcispedale S Maria Nuova, Italy
                      1. A Ghinoi (ghinoi.alessandra{at}asmn.re.it)
                      1. Arcispedale S Maria Nuova, Italy
                        1. G Restuccia (restuccia.giovanna{at}asmn.re.it)
                        1. Arcispedale S Maria Nuova, Italy
                          1. L Boiardi (boiardi.luigi{at}asmn.re.it)
                          1. Arcispedale S Maria Nuova, Italy

                            Abstract

                            Objective: To investigate potential associations between -463 G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical features of giant cell arteritis (GCA).

                            Methods: A total of 156 patients with biopsy-proven GCA who were residents of Reggio Emilia, Italy, and 235 population-based controls from the same geographic area were genotyped for -463 G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of polymyalgia rheumatica and severe ischemic complications (visual loss and/or cerebrovascular accidents).

                            Results: The distribution of the MPO-G/A genotype differed significantly between GCA patients and the controls (Pcorr = 0.003). Allele G was significantly more frequent in GCA patients than in the controls (P corr = 0.0002, OR 2.0, 95% CI 1.4-2.9). Homozygosity for the G allele was significantly more frequent in GCA patients than in controls (P corr = 0.0002, OR 2.2, 95% CI 1.4-3.4). No significant associations were found when GCA patients with and without polymyalgia rheumatica or with and without severe ischemic complications were compared.

                            Conclusion: Our findings show that the -463 G/A promoter polymorphism of the MPO gene is associated with GCA susceptibility and support a role for MPO in the pathophysiology of GCA.

                            • giant cell arteritis
                            • ischemic complication
                            • myeloperoxidase polymorphism
                            • myeloperoxise

                            Statistics from Altmetric.com

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.